Cognitive Ability, GeneralNCT07757529
Effect of Sage Extract Supplementation on Cognitive Function in Middle-Aged Men and Women
A study testing SageXtra in people with Cognitive Ability, General, run by ESM Technologies, LLC at 1 site in United States.
Trial summary
Sage (Salvia officinalis) has been reported to have antioxidant, anti-inflammatory, and neuroprotective properties. Several studies indicate that sage supplementation can improve cognitive function. However, more research is needed. Read more about this study
- Who is it for?
- Ages 40 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Cognitive Ability, General
- What is being tested?
- SageXtra
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 64 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Feb 2026to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- BMI 18.5-34.9 (inclusive) with a goal of being < 30 on average
- Subject agrees to maintain their existing dietary patterns throughout the study period.
- Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours before each test day.
- Subject is willing and able to comply with the study protocol.
- Has given voluntary, written, informed consent to participate in the study.
Who cannot join
- Individuals with a personal history of a psychiatric disorder.
- Individuals who are determined to have liver, renal, cardiovascular, or other metabolic disease.
- Current or recent (< 4 weeks) use of any dietary supplements (e.g., choline, lecithin, ginseng, ginkgo biloba, ashwagandha, Bacopa Monnieri, Paullina cupana, Rhodiola rosea, L-theanine, omega-3 fats, Prevagen, etc.), or currently prescribed medications (e.g., Adderall, Mydayis, Ritalin, Concerta, Mythylin, Provigil, Namenda), that may affect cognitive function (focus, concentration, memory, reaction time, energy, etc.).
- Alcohol consumption (>2 standard alcoholic drinks/day or >10 drinks/week) or drug abuse/dependence (including regular marijuana or THC use).
- Currently a smoker.
- Allergy or sensitivity to study product ingredients.
- Individuals who are cognitively impaired and/or who are unable to give informed consent.
- Any other condition which, in the PI's opinion, may adversely affect the subject's ability to complete the study, its measurements, or pose a significant risk to the subject.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Exercise & Sport Nutrition Lab - Texas A&M University
College Station, Texas, 77843
Richard B. Kreider, Ph.D., (979) 458-1498, rbkreider@tamu.edu
Christopher Rasmussen, M.S., (979) 458-1498, crasmussen@tamu.edu
About this study
Official title: Effect of SageXtra Supplementation on Cognitive Function in Middle-Aged Men and Women
Sage (Salvia officinalis) has been reported to have antioxidant, anti-inflammatory, and neuroprotective properties. Several studies indicate that sage supplementation can improve cognitive function. However, more research is needed. The purpose of this study is to examine how sage supplementation affects cognitive function and reaction times in middle-aged men and women.
Read the detailed description
To evaluate the effects of sage extract (sageXtra™) on cognitive function and psychomotor performance in middle-aged men and women, subjects (40-60 years) will receive 333 mg of SageXtra or placebo daily for 8 consecutive weeks.
- Conditions
- Cognitive Ability, General
- Being tested
- SageXtra, Placebo
- Keywords
- cognitive function, sage extract
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SageXtraDietary supplement
Also called sage extract powder
333 mg/day of SageXtra sage extract powder in two #0 capsules (167 mg/capsule).
PlaceboDietary supplement
333 mg/day of methylcellulose powder in two #0 capsules.
| Study group | Role | What they receive |
|---|---|---|
| Active | Experimental | 333 mg/day of SageXtra sage extract powder in two #0 capsules (167 mg/capsule). Receives: Dietary Supplement: SageXtra |
| Placebo | Placebo comparator | 333 mg/day of methylcellulose powder in two #0 capsules. Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
COMputerized Mental Performance ASsessment System (COMPASS) Test Battery
COMPASS consists of seven components including; 1) Immediate and Delayed Word Recall, 2) Delayed Word Recognition, 3) Delayed Picture Recognition, 4) Corsi Blocks Task, 5) Digit Vigilance, 6) Stroop Test and, 7) Choice Reaction Time evaluated via a computer program.
Measured: 4 weeks and 8 weeks
Secondary outcomes (1)
Physical performance
Evaluation of reaction time via a computer program where the subject has to press a key on the keyboard when an area of the computer screen lights up.
Measured: 4 weeks and 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Aug 2026
- Study start15 Feb 2026
- Primary completion31 Oct 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cognitive Ability, GeneralStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 64 participants (estimated)
Sponsor and investigators
- Lead sponsor
- ESM Technologies, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Exercise & Sport Nutrition Lab, Texas A&M University
- Responsible party
- Sponsor
- Investigators
- Kevin J. Ruff, Ph.D., Study director, ESM Technologies, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07757529
- Sponsor's protocol ID
- STUDY2025-0802
- Status last verified
- Aug 2026
- First submitted
- 30 Jul 2026
- Last updated
- 11 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 11 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of SageXtra Supplementation on Cognitive Function in Middle-Aged Men and Women
- ClinicalTrials.gov ID
- NCT07757529
- Acronym / sponsor ID
- STUDY2025-0802
- Conditions
- Cognitive Ability, General
- Keywords
- cognitive function, sage extract
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 64 participants (estimated)
- Lead sponsor
- ESM Technologies, LLCIndustry (pharma, biotech, devices)
- Collaborators
- Exercise & Sport Nutrition Lab, Texas A&M University
- Study start
- 15 Feb 2026 (actual)
- Primary completion
- 31 Oct 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 11 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Sage (Salvia officinalis) has been reported to have antioxidant, anti-inflammatory, and neuroprotective properties. Several studies indicate that sage supplementation can improve cognitive function. However, more research is needed. The purpose of this study is to examine how sage supplementation affects cognitive function and reaction times in middle-aged men and women.
Detailed description
To evaluate the effects of sage extract (sageXtra™) on cognitive function and psychomotor performance in middle-aged men and women, subjects (40-60 years) will receive 333 mg of SageXtra or placebo daily for 8 consecutive weeks.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active | Experimental | Dietary Supplement: SageXtra333 mg/day of SageXtra sage extract powder in two #0 capsules (167 mg/capsule). |
| Placebo | Placebo comparator | Dietary Supplement: Placebo333 mg/day of methylcellulose powder in two #0 capsules. |
Who may qualify
- Ages
- 40 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- BMI 18.5-34.9 (inclusive) with a goal of being < 30 on average
- Subject agrees to maintain their existing dietary patterns throughout the study period.
- Subject agrees to refrain from alcohol, caffeine, and strenuous exercise for 24 hours before each test day.
- Subject is willing and able to comply with the study protocol.
- Has given voluntary, written, informed consent to participate in the study.
Key exclusion criteria (8 listed)
- Individuals with a personal history of a psychiatric disorder.
- Individuals who are determined to have liver, renal, cardiovascular, or other metabolic disease.
- Current or recent (< 4 weeks) use of any dietary supplements (e.g., choline, lecithin, ginseng, ginkgo biloba, ashwagandha, Bacopa Monnieri, Paullina cupana, Rhodiola rosea, L-theanine, omega-3 fats, Prevagen, etc.), or currently prescribed medications (e.g., Adderall, Mydayis, Ritalin, Concerta, Mythylin, Provigil, Namenda), that may affect cognitive function (focus, concentration, memory, reaction time, energy, etc.).
- Alcohol consumption (>2 standard alcoholic drinks/day or >10 drinks/week) or drug abuse/dependence (including regular marijuana or THC use).
- Currently a smoker.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SageXtraAlso: sage extract powder333 mg/day of SageXtra sage extract powder in two #0 capsules (167 mg/capsule). | Dietary supplement | Active |
| Placebo333 mg/day of methylcellulose powder in two #0 capsules. | Dietary supplement | Placebo |
Primary outcome
COMputerized Mental Performance ASsessment System (COMPASS) Test Battery
Time frame: 4 weeks and 8 weeks
COMPASS consists of seven components including; 1) Immediate and Delayed Word Recall, 2) Delayed Word Recognition, 3) Delayed Picture Recognition, 4) Corsi Blocks Task, 5) Digit Vigilance, 6) Stroop Test and, 7) Choice Reaction Time evaluated via a computer program.
1 secondary outcome
Physical performance
Time frame: 4 weeks and 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Cognitive Ability, General
Not yet recruiting
EFFET - Study of Executive Functions Regarding the Usability and User Experience of Assistive Technologies Among the Elderly
Gerontology, Cognitive Ability General
RecruitingObservational study
Automated IADL Sensing to Refine Measurement of Older Adult Daily Activity
Cognitive Ability General, Functional Abilities
Active, not recruitingObservational study
Associations Between Dietary Intake and Cardiometabolic and Gut Microbiota Outcomes
Cardiometabolic Risk Factors, Skin Condition
Recruiting
Investigating the Effects of Beef Consumption on Cognitive and Brain Health
Dietary Intervention, Dietary Proteins
Active, not recruiting
The Bucharest Early Intervention Project
Cognitive Ability, General, Psychiatric and/or Mood Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kevin J. Ruff, Ph.D. study director
ESM Technologies, LLC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SageXtra in people with Cognitive Ability, General, run by ESM Technologies, LLC at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 11 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Richard B. Kreider, Ph.D. ((979) 458-1498, rbkreider@tamu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
COMputerized Mental Performance ASsessment System (COMPASS) Test Battery (time frame: 4 weeks and 8 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2026; AzTrials last refreshed its copy on 30 Oct 2026.